Repository logo

Browsing by Author "Estol, Conrado"

Now showing 1 - 1 of 1
  • Long‐term efficacy and safety of eslicarbazepine acetate monotherapy for adults with newly diagnosed focal epilepsy: An open‐label extension study
    Publication . Trinka, Eugen; Rocamora, Rodrigo; Chaves, João; Moreira, Joana; Ikedo, Fábio; Soares‐da‐Silva, Patrício; Estol, Conrado; Newton, Mark; Carne, Ross; Kowacs, Pedro; Petrova, Dorina; Syankov, Dimitar; Maslarov, Dimitar; Stanev, Slavi; Lasso, Jorge; Bašić, Silvio; Bar, Michal; Vyskočilová, Dana; Pazdera, Ladislav; Haldre, Sulev; Kaarina Kälviäinen, Reetta; Peltola, Jukka; Georges Maillard, Louis; Deckert‐Schmitz, Maria; Springub, Joachim; Barcs, Gábor; Ménes, Andrea; Tóth, Marianna; Giallonardo, Anna Teresa; Paganini, Marco; Asmane, Santa; Logina, Lnara; Meilute Lescinskiene, Loreta; Cruz, Ana; Umeres, Hugo; Czapiński, Piotr; Trzebińska‐Frydrychowska, Ewa; Sales, Francisco; Falup‐Pecurariu, Cristian Gavril; Silviu Manescu, Emilian; Roceanu, Adina‐Maria; Odinak, Miroslav; Tretyakova, Evgeniya; Volkova, Larisa; Lebedeva, Anna; Lipatova, Liudmila; Bogdanov, Enver; Vladimirovna Polezhaeva, Tatiana; Gebauer‐Bukurov, Ksenija; Jovanovic‐Mihajlovic, Natalija; Milovanovic, Maja; Spasic, Mirjana; Lipovský, L'Ubomír; Perichtová, Magdaléna; Chamilová, Jana; Balaguer, Ernest; Ugarte, Antonio; Dubenko, Andriy; Kharchuk, Sergii; Moroz, Svitlana; Shkrobot, Svitlana; Mar'yenko, Lidiya; Litovchenko, Tetyana; Cock, Hannah
    Objective: To assess the efficacy, safety, and tolerability of eslicarbazepine acetate (ESL) monotherapy during long-term treatment. Methods: An open-label extension (OLE) study was conducted in adults completing a phase 3, randomized, double-blind, noninferiority trial, during which they had received monotherapy with either once-daily ESL or twice-daily controlled-release carbamazepine (CBZ-CR) for newly diagnosed focal epilepsy. In the OLE study, all patients received ESL (800-1600 mg/d) for 2 years. Primary efficacy outcome was retention time (from baseline of the OLE study). Secondary efficacy assessments included seizure freedom rate (no seizures during the OLE study) and responder rate (≥50% seizure frequency reduction from baseline of double-blind trial). Safety assessments included evaluation of treatment-emergent adverse events (TEAEs). Results: Of 206 randomized patients, 96 who received ESL in the double-blind trial (ESL/ESL) and 88 who received CBZ-CR in the double-blind trial (CBZ-CR/ESL) were treated with ESL monotherapy (89.3% overall). Treatment retention time was similar between groups, with low probability of ESL withdrawal overall (<0.07 at any time). After 24 months, the probability of ESL withdrawal was 0.0638 (95% confidence interval [CI] = 0.0292-0.1366) in the ESL/ESL group and 0.0472 (95% CI = 0.0180-0.1210) in the CBZ-CR/ESL group. Seizure freedom rates were 90.6% (ESL/ESL) and 80.7% (CBZ-CR/ESL; P = .0531). Responder rates remained >80% in both groups throughout the study. Incidence of serious TEAEs was similar between groups (7.3% vs 5.7%; 0% vs 1.1% possibly related), as were the incidences of TEAEs considered at least possibly related to treatment (17.7% vs 18.2%) and TEAEs leading to discontinuation (3.1% vs 4.5%). The types of TEAEs were generally consistent with the known safety profile of ESL. Significance: ESL monotherapy was efficacious and generally well tolerated over the long term, including in patients who transitioned from CBZ-CR monotherapy. No new safety concerns emerged.
    2020Journal article Open access Show more